iiinova — where your digital self keeps evolving

psybalazs.bsky.social @psybalazs.bsky.social · 26/03/2025

Got interviewed by the Microdose newsletter on the intersection of #psychedelic and #placebo research and on why psychedelic research should revisit the long forgotten Zelen design to solve the "know-cebo" problem. Enjoy! themicrodose.substack.com/p/the-power-...

themicrodose.substack.com

The power of “know-cebo”: 5 Questions for data scientist Balázs Szigeti

Szigeti discusses expectancy effects, unblinding, and how researchers might design better studies on psychedelics.

2188

psybalazs.bsky.social @psybalazs.bsky.social · 22/03/2025

Instead of making a bunch of separate #psilocybin vs #alcohol / #nicotine / #gambling / #porn #addiction trials, it would make sense to run a single trial where patients with ANY form of addiction are recruited.

120

psybalazs.bsky.social @psybalazs.bsky.social · 04/02/2025

I want to highlight a finding from (tinyurl.com/37n77d9b) that IMO did not receive enough attention in #psychedelic trial geek circles: it shows that the #placebo effect is much smaller in psychedelic #depression trials than in trials with traditional #antidepressants (SSRIs/SNRIs).

tinyurl.com

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network m...

PROSPERO, CRD42023469014.

120